Yungjin Pharmaceutical announced on the 22nd that it has completed the license application for a generic version of Boehringer Ingelheim's ‘Ofev Soft Cap (Ofev)’ that it had developed by changing the original drug’s soft capsule formulation into a tablet.

As a global blockbuster product, Ofev (nintedanib) is widely used in combination with pirfenidone to delay the decline in lung function in patients with idiopathic pulmonary fibrosis.

Despite being a non-reimbursed drug in Korea, Ofev generated sales of around KRW 6 billion last year and is in such high demand that a petition is underway for its reimbursement.

Yungjin Pharmaceutical was the first Korean pharmaceutica